.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,205,302

« Back to Dashboard
Patent 7,205,302 protects UPTRAVI and is included in one NDA.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 7,205,302

Title:Heterocyclic compound derivatives and medicines
Abstract: The present invention provides a compound which is useful as a PGI.sub.2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: ##STR00001## (R.sup.1 and R.sup.2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR.sup.5, O, S, or ethylene, R.sup.5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH.sub.2, R.sup.3 and R.sup.4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.
Inventor(s): Asaki; Tetsuo (Kyoto, JP), Hamamoto; Taisuke (Osaka, JP), Kuwano; Keiichi (Osaka, JP)
Assignee: Nippon Shinyaku Co., Ltd. (Kyoto, JP)
Application Number:10/476,196
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 7th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-001Dec 21, 2015RXNo7,205,302► subscribeYY METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-002Dec 21, 2015RXNo7,205,302► subscribeYY METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
Actelion Pharms Ltd
UPTRAVI
selexipag
TABLET;ORAL207947-003Dec 21, 2015RXNo7,205,302► subscribeYY METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,205,302

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2001-129765Apr 26, 2001
PCT Information
PCT FiledApril 25, 2002PCT Application Number:PCT/JP02/04118
PCT Publication Date:November 07, 2002PCT Publication Number: WO02/088084

International Patent Family for Patent: 7,205,302

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil0209249► subscribe
BrazilPI0209249► subscribe
Canada2445344► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc